AtriCure Q3 revenue $70.5M, +28.7% YoY; adj EPS -$0.23; FY guide reaffirmed

AtriCure, Inc.

2021-Q3 EPS reported $1.39 revenue$201,111,000

Revenue $70.5M, up 28.7% YoY (28.6% constant currency); U.S. $57.5M (+28.7%), intl $12.9M (+28.5%).
GAAP income from operations $98.7M vs loss $4.0M, driven by $189.9M fair value credit and $82.3M impairment charge.
Adjusted EBITDA $0.7M positive vs $4.2M positive; adjusted loss per share $0.23 vs $0.11 loss.
Maintains FY2021 revenue guidance $270-275M (~31-33% growth); adj EBITDA loss ~$10M; adj EPS loss ~$1.20.
CEO cites growth in Cryo Nerve Block and Hybrid AF accounts; delta variant impacts felt across the country.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.